Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 01, 2026 08:30 ET | Source: Celcuity Inc.

Celcuity to Hold Conference Call to Discuss Results for the PIK3CA Mutant Cohort of the Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib Regimens in HR+/HER- Advanced Breast Cancer on June 2, 2026

MINNEAPOLIS, June 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple...
June 01, 2026 08:15 ET | Source: Greenwich LifeSciences, Inc.

Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026

STAFFORD, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
May 29, 2026 08:00 ET | Source: Medidata Solutions, Inc.

Medidata Champions Collaborative Scientific Advancement at ASCO with New Research on Oncology Protocol Optimization and CAR T Efficacy

NEW YORK, May 29, 2026 (GLOBE NEWSWIRE) -- Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, will present two poster presentations...
May 28, 2026 09:30 ET | Source: Stemline Therapeutics, Inc.

Menarini Group Presents New Data from the Phase 1b/2 ELEVATE Study of Elacestrant (ORSERDU®) in Combination with Capivasertib in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Encouraging safety and preliminary efficacy analysis from the elacestrant and capivasertib Phase 1b regimen of the ELEVATE study will be presented.The efficacy data highlight how the combination of...
May 27, 2026 07:00 ET | Source: LeonaBio, Inc.

LeonaBio to Participate in Upcoming Medical and Industry Meetings in June

BOTHELL, Wash., May 27, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high...
May 27, 2026 05:00 ET | Source: NUCLIDIUM AG

NUCLIDIUM Announces Closing of Series B Extension Bringing Total Round to CHF 105 Million

NUCLIDIUM announced a CHF 26.4 million extension led by existing investors to accelerate clinical development of NU101 and NU201 radiotheranostic programs.
May 14, 2026 09:19 ET | Source: Research and Markets

CD73 Inhibitors Pipeline Competitor Analysis Report 2026: Active R&D Programs by R&D Phase and Profile of Inhibitors by Drug Modality

Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of CD73 Inhibitors" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report about CD73 Inhibitors...
May 14, 2026 08:00 ET | Source: Stemline Therapeutics, Inc.

Menarini Group Announces New Data at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

Data spans seven presentations across both solid tumors and hematologic malignancies, providing updates on the potential benefit these therapies may bring to patients. Data from the elacestrant plus...
May 07, 2026 08:00 ET | Source: ALX Oncology

ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression

- Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven development strategy for evorpacept - - Findings are consistent with previous results from the...
April 30, 2026 08:00 ET | Source: ALX Oncology

ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026

- Company Will Discuss Data and Report First Quarter 2026 Financial Results on May 8 - SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology";...